James Kovacic
Research Subjects
James Kovacic has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Shepherd
Department of Urology, Royal North Shore Hospital, Sydney 2065, Australia
2 shared publications - Ankur Dhar
Westmead Hospital Sydney New South Wales Australia
2 shared publications - Ahmed Goolam
North Shore Urology Research Group, Sydney, Australia
1 shared publication Amanda Chung
Royal North Shore Hospital St Leonards NSW Australia
1 shared publicationAndrew Shepherd
Royal North Shore Hospital St Leonards NSW Australia
1 shared publicationAnkur Dhar
Royal North Shore Hospital St Leonards NSW Australia
1 shared publication
Latest Publications
- Open Access
- 11 April 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (4) , 286-292
Salvage robotic-assisted radical cystectomy is safe in patients with history of pelvic irradiation
Objectives: To describe the surgical approach and perioperative outcomes of a multicenter series evaluating a robotic-assisted approach to radical cystectomy with total intracorporeal urinary diversion in the setting of prior pelvic radiotherapy. Materials and methods: We analyzed our prospective cystectomy database for patients who underwent robotic-assisted radical cystectomy for bladder cancer after radiotherapy between 2018 and 2022. Demographic information and data regarding preoperative factors including stage of disease, preoperative hydronephrosis, and history of pelvic radiotherapy were collected via review of electronic medical records. All operations were performed by 1 of 2 experienced urologists using the da Vinci X, Xi, or Si surgical platforms. Results: Ten patients were identified for this study. The median age of participants was 73.5 years (range, 41–84 years). The median American Society of Anesthesiologists classification score was 3 (range, 3–4). The median Charlson Comorbidity Index was 6 (range, 2–12). Among the patients, 4 out of 10 patients (40%) had muscle invasive bladder cancer before salvage surgery. Intracorporeal ileal conduit urinary diversion was performed in 8 patients, whereas 2 patients underwent intracorporeal neobladder formation. Median intraoperative blood loss was 250 mL (range, 150–600 mL), and median operative duration was 390 minutes (range, 195–450 minutes). The overall 30-day complication rate was 60% with a Clavien-Dindo grade ≥3 complication rate of 15%. Perioperative mortality was 0%. Median duration of follow-up was 210 days (range, 60–1580 days). Conclusions: This series describing the outcomes of salvage robotic-assisted radical cystectomy using total intracorporeal urinary diversion demonstrates the safety of this technique. Further studies with long-term follow-up, including oncological outcomes, are required to support the widespread adoption of this procedure.
- 11 April 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (4) , 286-292
Open AccessSalvage robotic-assisted radical cystectomy is safe in patients with history of pelvic irradiation
Objectives: To describe the surgical approach and perioperative outcomes of a multicenter series evaluating a robotic-assisted approach to radical cystectomy with total intracorporeal urinary diversion in the setting of prior pelvic radiotherapy. Materials and methods: We analyzed our prospective cystectomy database for patients who underwent robotic-assisted radical cystectomy for bladder cancer after radiotherapy between 2018 and 2022. Demographic information and data regarding preoperative factors including stage of disease, preoperative hydronephrosis, and history of pelvic radiotherapy were collected via review of electronic medical records. All operations were performed by 1 of 2 experienced urologists using the da Vinci X, Xi, or Si surgical platforms. Results: Ten patients were identified for this study. The median age of participants was 73.5 years (range, 41–84 years). The median American Society of Anesthesiologists classification score was 3 (range, 3–4). The median Charlson Comorbidity Index was 6 (range, 2–12). Among the patients, 4 out of 10 patients (40%) had muscle invasive bladder cancer before salvage surgery. Intracorporeal ileal conduit urinary diversion was performed in 8 patients, whereas 2 patients underwent intracorporeal neobladder formation. Median intraoperative blood loss was 250 mL (range, 150–600 mL), and median operative duration was 390 minutes (range, 195–450 minutes). The overall 30-day complication rate was 60% with a Clavien-Dindo grade ≥3 complication rate of 15%. Perioperative mortality was 0%. Median duration of follow-up was 210 days (range, 60–1580 days). Conclusions: This series describing the outcomes of salvage robotic-assisted radical cystectomy using total intracorporeal urinary diversion demonstrates the safety of this technique. Further studies with long-term follow-up, including oncological outcomes, are required to support the widespread adoption of this procedure.
- 26 December 2023
- Published by Wiley in BJU International
- Vol. 133 (S4) , 37-43
Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double‐blind randomized controlled trial protocol
Objectives: To determine, firstly, whether MV140 reduces rates of recurrent urinary tract infections (rUTIs) in patients older than 65 years, measured as the number of urinary tract infections (UTIs) detected over 12 months following the completion of a 3‐month treatment course and, additionally, to assess the number of re‐admissions to the emergency department, the rate of antibiotic use for UTIs, the safety profile of MV140, and quality of life. Materials and Methods: This is a multicentre, double‐blind, randomized controlled trial with two arms. Patients will be randomized and allocated to receive either a 3‐month course of MV140 or placebo (two sublingual sprays daily). Participants will have 3‐monthly consultations with the investigator for 12 months to assess differences in rates of rUTIs between the two groups. Study candidates will be identified and recruited from inpatient and outpatient clinics across Sydney via referral to the investigation team. After obtaining consent, participants will undergo initial study consultations including urine microscopy and culture, uroflowmetry, and bladder scan to assess postvoid residual urine volume. Participants will be randomized and provided with a unique trial number. Electronic medical records will be reviewed to collect relevant information. Participants will be provided with a study diary to record relevant data. Results: Follow‐up consultations will be conducted every 3 months for a 12‐month duration, during which the study diary will be reviewed. These follow‐up consultations will primarily occur via telephone review, however, there will be flexibility for in‐person reviews for participants who find telephone consultation prohibitively difficult. Conclusion: This is a multicentre, double‐blinded, randomised control trial, the first in Australia to assess the safety and efficacy of MV140 Uromune vaccine in prevention of recurrent UTIs. Results have been promissing in the global literatures.
- 26 December 2023
- Published by Wiley in BJU International
- Vol. 133 (S4) , 37-43
Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double‐blind randomized controlled trial protocol
Objectives: To determine, firstly, whether MV140 reduces rates of recurrent urinary tract infections (rUTIs) in patients older than 65 years, measured as the number of urinary tract infections (UTIs) detected over 12 months following the completion of a 3‐month treatment course and, additionally, to assess the number of re‐admissions to the emergency department, the rate of antibiotic use for UTIs, the safety profile of MV140, and quality of life. Materials and Methods: This is a multicentre, double‐blind, randomized controlled trial with two arms. Patients will be randomized and allocated to receive either a 3‐month course of MV140 or placebo (two sublingual sprays daily). Participants will have 3‐monthly consultations with the investigator for 12 months to assess differences in rates of rUTIs between the two groups. Study candidates will be identified and recruited from inpatient and outpatient clinics across Sydney via referral to the investigation team. After obtaining consent, participants will undergo initial study consultations including urine microscopy and culture, uroflowmetry, and bladder scan to assess postvoid residual urine volume. Participants will be randomized and provided with a unique trial number. Electronic medical records will be reviewed to collect relevant information. Participants will be provided with a study diary to record relevant data. Results: Follow‐up consultations will be conducted every 3 months for a 12‐month duration, during which the study diary will be reviewed. These follow‐up consultations will primarily occur via telephone review, however, there will be flexibility for in‐person reviews for participants who find telephone consultation prohibitively difficult. Conclusion: This is a multicentre, double‐blinded, randomised control trial, the first in Australia to assess the safety and efficacy of MV140 Uromune vaccine in prevention of recurrent UTIs. Results have been promissing in the global literatures.
- Open Access
- 1 September 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (3) , 287-289
Open Approaches to Radical Nephrectomies: A Case Report of Bilateral T3b Renal Cell Carcinoma
- 1 September 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (3) , 287-289
Open AccessOpen Approaches to Radical Nephrectomies: A Case Report of Bilateral T3b Renal Cell Carcinoma
- Open Access
- 25 November 2022
- Published by Elsevier in Urology Case Reports
- Vol. 46, 102285
A rare case of co-secreting adrenocortical oncocytoma
- 25 November 2022
- Published by Elsevier in Urology Case Reports
- Vol. 46, 102285
Open AccessA rare case of co-secreting adrenocortical oncocytoma
- 21 August 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (11) , 3033-3036
Midline extraperitoneal approach to retroperitoneal pathology ‐ broadening the horizons
We present an explanation of approach to open midline extraperitoneal surgery for the management of retroperitoneal pathology. Included are diagrammatic and intra-operative images to better explain the approach, as well as discussion regarding the technique.
- 21 August 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 92 (11) , 3033-3036
Midline extraperitoneal approach to retroperitoneal pathology ‐ broadening the horizons
We present an explanation of approach to open midline extraperitoneal surgery for the management of retroperitoneal pathology. Included are diagrammatic and intra-operative images to better explain the approach, as well as discussion regarding the technique.
- 10 June 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (2) , 143-145
Iatrogenic Renal Rupture in Conduitoscopy - A Diagnostic Trauma
- 10 June 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (2) , 143-145
Iatrogenic Renal Rupture in Conduitoscopy - A Diagnostic Trauma
- 4 June 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (10) , 2101-2103
Case report: acute left‐sided Amyand's hernia in an elderly patient
- 4 June 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (10) , 2101-2103
Case report: acute left‐sided Amyand's hernia in an elderly patient